Literature DB >> 9271436

Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene.

G S Watts1, R O Pieper, J F Costello, Y M Peng, W S Dalton, B W Futscher.   

Abstract

O6-Methylguanine DNA methyltransferase (MGMT) repairs the mutagenic and cytotoxic O6-alkylguanine lesions produced by environmental carcinogens and the chemotherapeutic nitrosoureas. As such, MGMT-mediated repair of O6-alkylguanine lesions constitutes a major form of resistance to nitrosourea chemotherapy and makes control of MGMT expression of clinical interest. The variability of expression in cell lines and tissues, along with the ease with which the MGMT phenotype reverts under various conditions, suggests that MGMT is under epigenetic control. One such epigenetic mechanism, 5-methylation of cytosines, has been linked to MGMT expression. We have used an isogenic human multiple myeloma tumor cell line model composed of an MGMT-positive parent cell line, RPMI 8226/S, and its MGMT-negative variant, termed 8226/V, to study the control of MGMT expression. The loss of MGMT activity in 8226/V was found to be due to the loss of detectable MGMT gene expression. Bisulfite sequencing of the MGMT CpG island promoter revealed large increases in the levels of CpG methylation within discrete regions of the 8226/V MGMT CpG island compared to those in 8226/S. These changes in CpG methylation are associated with local heterochromatinization of the 8226/V MGMT transcription start site and provide a likely mechanism for the loss of MGMT transcription in 8226/V.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271436      PMCID: PMC232409          DOI: 10.1128/MCB.17.9.5612

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  34 in total

1.  Lack of the DNA repair protein O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors.

Authors:  J R Silber; A Blank; M S Bobola; B A Mueller; D D Kolstoe; G A Ojemann; M S Berger
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Measurement of O6-alkylguanine-DNA alkyltransferase activity in human cells and tumor tissues by restriction endonuclease inhibition.

Authors:  R S Wu; S Hurst-Calderone; K W Kohn
Journal:  Cancer Res       Date:  1987-12-01       Impact factor: 12.701

3.  CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation.

Authors:  S M Iguchi-Ariga; W Schaffner
Journal:  Genes Dev       Date:  1989-05       Impact factor: 11.361

4.  CpG islands in vertebrate genomes.

Authors:  M Gardiner-Garden; M Frommer
Journal:  J Mol Biol       Date:  1987-07-20       Impact factor: 5.469

5.  Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine.

Authors:  K Tano; S Shiota; J Collier; R S Foote; S Mitra
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

6.  Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter.

Authors:  F Watt; P L Molloy
Journal:  Genes Dev       Date:  1988-09       Impact factor: 11.361

7.  Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.

Authors:  M E Dolan; R C Moschel; A E Pegg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

8.  Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.

Authors:  R S Day; C H Ziolkowski; D A Scudiero; S A Meyer; A S Lubiniecki; A J Girardi; S M Galloway; G D Bynum
Journal:  Nature       Date:  1980-12-25       Impact factor: 49.962

9.  Comparison of O-6-methylguanine DNA methyltransferase (MGMT) mRNA levels in Mer+ and Mer- human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique.

Authors:  R O Pieper; B W Futscher; Q Dong; T M Ellis; L C Erickson
Journal:  Cancer Commun       Date:  1990

10.  Response of cultured human cell lines from rhabdomyosarcoma xenografts to treatment with chloroethylnitrosoureas.

Authors:  D G Smith; T P Brent
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

View more
  57 in total

Review 1.  Flipping the epigenetic switch.

Authors:  Frederick E Domann; Bernard W Futscher
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

2.  Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma.

Authors:  Toshihito Ohno; Junji Hiraga; Haruhiko Ohashi; Chiho Sugisaki; Eika Li; Haruhiko Asano; Tastuya Ito; Hirokazu Nagai; Yoriko Yamashita; Naoyoshi Mori; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

3.  Confluence-induced alterations in CpG island methylation in cultured normal human fibroblasts.

Authors:  R O Pieper; K A Lester; C P Fanton
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

Review 4.  Assessing MGMT methylation status and its current impact on treatment in glioblastoma.

Authors:  Anna S Berghoff; Johannes A Hainfellner; Christine Marosi; Matthias Preusser
Journal:  CNS Oncol       Date:  2015

5.  Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.

Authors:  Rui-Chao Chai; Ke-Nan Zhang; Yu-Qing Liu; Fan Wu; Zheng Zhao; Kuan-Yu Wang; Tao Jiang; Yong-Zhi Wang
Journal:  CNS Neurosci Ther       Date:  2018-08-16       Impact factor: 5.243

6.  Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.

Authors:  J L Blanc; M Wager; J Guilhot; S Kusy; B Bataille; T Chantereau; F Lapierre; C J Larsen; L Karayan-Tapon
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

7.  Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.

Authors:  Luca Morandi; Enrico Franceschi; Dario de Biase; Gianluca Marucci; Alicia Tosoni; Mario Ermani; Annalisa Pession; Giovanni Tallini; Alba Brandes
Journal:  BMC Cancer       Date:  2010-02-18       Impact factor: 4.430

8.  Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.

Authors:  K A van Nifterik; J van den Berg; W F van der Meide; N Ameziane; L E Wedekind; R D M Steenbergen; S Leenstra; M V M Lafleur; B J Slotman; L J A Stalpers; P Sminia
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

9.  A female adnexal tumor of probable Wolffian origin showing positive O-6-methylguanine-DNA methyltransferase methylation.

Authors:  Min Jung Kwon; Min Jeong Yun; Min Kyu Kim
Journal:  Obstet Gynecol Sci       Date:  2016-07-13

10.  Glioblastoma Multiforme Oncogenomics and Signaling Pathways.

Authors:  Okezie O Kanu; Betsy Hughes; Chunhui Di; Ningjing Lin; Jinrong Fu; Darell D Bigner; Hai Yan; Cory Adamson
Journal:  Clin Med Oncol       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.